SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 181 filers reported holding SANGAMO THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $0 | -100.0% | 865 | -96.3% | 0.00% | – |
| Q1 2024 | $15 | -21.1% | 23,437 | -36.8% | 0.00% | – |
| Q4 2023 | $19 | -5.0% | 37,090 | +5.8% | 0.00% | – |
| Q3 2023 | $20 | -80.8% | 35,051 | -56.2% | 0.00% | – |
| Q2 2023 | $104 | +395.2% | 80,078 | +536.1% | 0.00% | – |
| Q1 2023 | $21 | -72.0% | 12,589 | -48.0% | 0.00% | – |
| Q4 2022 | $75 | -99.9% | 24,210 | -10.2% | 0.00% | – |
| Q3 2022 | $131,000 | +18.0% | 26,964 | +0.2% | 0.00% | – |
| Q2 2022 | $111,000 | +58.6% | 26,919 | +121.2% | 0.00% | – |
| Q1 2022 | $70,000 | +7.7% | 12,168 | +37.9% | 0.00% | – |
| Q4 2021 | $65,000 | 0.0% | 8,826 | +21.5% | 0.00% | – |
| Q3 2021 | $65,000 | -66.3% | 7,266 | -55.3% | 0.00% | – |
| Q2 2021 | $193,000 | +9550.0% | 16,256 | +7092.9% | 0.00% | – |
| Q1 2021 | $2,000 | -97.6% | 226 | -95.8% | 0.00% | – |
| Q4 2020 | $83,000 | – | 5,347 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rokos Capital Management LLP | 6,474,348 | $11,394,852 | 0.84% |
| WASATCH ADVISORS LP | 13,642,417 | $24,010,654 | 0.15% |
| Avidity Partners Management LP | 2,470,000 | $4,347,200 | 0.14% |
| Acrisure Capital Management, LLC | 75,832 | $133,464 | 0.14% |
| Golden State Equity Partners | 135,765 | $238,946 | 0.13% |
| Long Focus Capital Management, LLC | 1,072,000 | $1,886,720 | 0.11% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $78,008 | 0.10% |
| CAXTON ASSOCIATES LP | 288,218 | $507,264 | 0.08% |
| XTX Topco Ltd | 206,334 | $363,148 | 0.08% |
| Rhenman & Partners Asset Management AB | 314,157 | $534,067 | 0.06% |